Intense Lilly, Novo rivalry throws India weight-loss drug race wide open

Eli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outreach and partnerships. Lilly's Mounjaro launched early and is leading sales. Novo Nordisk is cutting prices and launching Ozempic. Generic versions are expected next year, intensifying the competition in this price-sensitive market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dr5jXoy
via IFTTT